Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue plasminogen activator: a new thrombolytic agent.

S J Crabbe1, C C Cloninger

  • 1Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, PA 19107.

Clinical Pharmacy
|May 1, 1987
PubMed
Summary

Tissue plasminogen activator (t-PA) is a clot-specific thrombolytic agent. Recombinant t-PA (rt-PA) shows promise for acute myocardial infarction, demonstrating greater efficacy than streptokinase, though optimal dosing requires further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validity of information received from pharmaceutical companies.

DICP : the annals of pharmacotherapy·1990
Same author

Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.

Pharmacotherapy·1990
Same author

Use of a proprietary database to examine lengths of hospital stay of patients who received drug therapy for acute myocardial infarction.

American journal of hospital pharmacy·1989
Same author

Fee-for-service activities provided by drug information centers.

American journal of hospital pharmacy·1988

Area of Science:

  • Biochemistry
  • Pharmacology
  • Clinical Medicine

Background:

  • Tissue plasminogen activator (t-PA) is a serine protease crucial for fibrinolysis.
  • Its clot-specific binding to fibrin-plasminogen complexes differentiates it from older thrombolytics like streptokinase and urokinase.
  • Understanding t-PA's properties is key for its therapeutic application in thromboembolic disorders.

Purpose of the Study:

  • To review the chemistry, pharmacology, pharmacokinetics, clinical efficacy, and safety of tissue plasminogen activator (t-PA).
  • To evaluate the role of recombinant t-PA (rt-PA) in treating acute myocardial infarction and other thromboembolic conditions.
  • To compare the efficacy and safety of rt-PA with streptokinase.

Main Methods:

  • Review of existing literature on t-PA, including preclinical and clinical trial data.
  • Analysis of pharmacological properties, including clot specificity and dose-dependency.
  • Comparison of clinical outcomes, adverse effects, and contraindications of rt-PA versus streptokinase.

Main Results:

  • t-PA exhibits clot specificity by binding to fibrin-plasminogen, catalyzing plasminogen to plasmin.
  • Intravenous rt-PA appears more effective than intravenous streptokinase for acute myocardial infarction.
  • Similar rates of hemorrhage, reperfusion arrhythmias, and reocclusion are reported for both agents; safety and efficacy are dose-related.

Conclusions:

  • rt-PA demonstrates potential as a superior thrombolytic agent for acute myocardial infarction compared to streptokinase.
  • Further research is necessary to establish optimal dosing for rt-PA to maximize efficacy and minimize hemostatic defects.
  • Preliminary data suggest rt-PA is a promising agent for various thromboembolic disorders.

Related Experiment Videos